Mounjaro®
Starting from £179.99/mo
Start journey Learn moreBoth semaglutide and tirzepatide have strong safety records established in large clinical trials and are licensed in the UK for weight management as prescription-only medicines — neither is categorically safer than the other. The honest answer is that their risk profiles overlap significantly, with a few meaningful differences that a prescriber weighs for each individual. As prescription medicines, they require a clinical assessment before anyone is issued a prescription; a clinician decides which is appropriate for you, taking your full health picture into account. Our clinical team works through exactly this with every patient who comes to nume.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A lot of people arrive at this question assuming tirzepatide must be riskier because it works on two receptors (GIP and GLP-1) while semaglutide works on one. Two mechanisms sounds more complicated, and complicated sounds more dangerous. It's a reasonable instinct, but the clinical evidence doesn't bear it out. The SURMOUNT-1 trial, which followed thousands of adults on tirzepatide for 72 weeks, found a side-effect profile that was broadly similar to semaglutide's, dominated by the same class of gastrointestinal symptoms. Having two active pathways does not appear to translate into a meaningfully higher burden of adverse effects.
That said, "similarly safe overall" is not the same as "identical in every respect." There are genuine differences in how the two medicines interact with other drugs and in a handful of specific clinical situations, and those differences are exactly what a prescriber needs to factor in. You can read a fuller breakdown of how the two treatments compare on results and tolerability on our semaglutide vs tirzepatide comparison page.
The core side-effect pattern is shared: nausea, loose stools, constipation, indigestion, reduced appetite, and occasional fatigue are reported with both medicines, particularly in the first weeks or after a dose increase. Both carry the same serious but infrequent risks, acute pancreatitis is one the MHRA highlighted in a Drug Safety Update issued for GLP-1 medicines in January 2026, advising anyone who develops severe, persistent stomach pain radiating to the back to seek urgent medical attention.
The most clinically significant difference sits in drug interactions. Women taking oral contraceptives alongside tirzepatide are advised to add a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, because the pill's absorption may be reduced as the gut slows. The equivalent caution is not considered necessary with semaglutide, a distinction our page on whether semaglutide is safer than tirzepatide explores in more detail. NHS England guidance also raises the question of transdermal HRT forms for women on tirzepatide (patches or gels rather than oral tablets) worth raising with your prescriber if relevant. The NHS England guidance on weight-management injections sets this out clearly for both medicines.
Both medicines are unsuitable during pregnancy, while breastfeeding, or when trying to conceive. Neither is licensed for under-18s. Anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not take either medicine.
The table below draws on data from the NHS, NICE, and published trial evidence. Numbers reflect clinical trial findings and are not guarantees of individual outcomes.
| Factor | Semaglutide (Wegovy) | Tirzepatide (Mounjaro) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| Most common side effects | GI-led: nausea, diarrhoea, constipation, vomiting | GI-led: nausea, diarrhoea, constipation, vomiting |
| Pancreatitis risk | Infrequent but known; seek help for severe persistent abdominal pain | Infrequent but known; seek help for severe persistent abdominal pain |
| Oral contraceptive interaction | No specific MHRA caution identified | Add non-oral contraception for 4 weeks at start and after each dose increase |
| Pregnancy / breastfeeding | Not recommended | Not recommended |
| Under-18s | Not licensed | Not licensed |
Sources: NHS semaglutide medicines page; NHS tirzepatide medicines page; NICE appraisals TA875 and TA1026.
There is no universal answer to the question of whether semaglutide or tirzepatide is safer, and if you want a detailed look at how to weigh up the two options, our page on which is best, tirzepatide or semaglutide, covers the key considerations side by side. Our page on choosing between semaglutide and tirzepatide covers those personal factors in more depth.
At nume, a GPhC-registered Independent Prescriber reads every consultation personally. They consider drug interactions, contraindications, and your full clinical picture before any prescription is issued, the kind of assessment that turns the general information on this page into a decision that actually applies to you. If you want to explore your options, starting a free consultation is the place to begin. For a broader look at what's available, our weight-loss treatments overview is a good starting point.
If you'd like to understand how the two medicines compare on effectiveness rather than safety, our strength and results comparison goes into that in detail. And if cost is a factor, the Mounjaro vs Wegovy pricing page explains what you'd typically be looking at. Questions about anything here? Our team is always reachable via our contact page.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.